Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression
Author:
Funder
Roche
Boehringer Ingelheim
AstraZeneca
BMS
Merck
Novartis
Pfizer
Sanofi
Astellas
Astra Zeneca
Abbvie
Amgen
Biogen
Celgene
Lilly
GSK
Ignyta
Merck KGaA
MSD
Pharma Mar
Spectrum Pharmaceuticals
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference33 articles.
1. Brain metastases in oncogene-addicted non-small cell lung cancer patients: incidence and treatment;Remon;Front Oncol,2018
2. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era;Remon;Cancer Treat Rev,2017
3. Clinical utility of cerebrospinal fluid cell-free DNA as liquid biopsy for leptomeningeal metastases in ALK-rearranged NSCLC;Zheng;J Thorac Oncol,2019
4. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer;Lee;Cancer,2010
5. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial;Trédan;Ann Oncol,2019
Cited by 56 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan;JCO Precision Oncology;2024-01
2. Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients;World Journal of Surgical Oncology;2023-11-25
3. Use of comprehensive genomic profiling for biomarker discovery for the management of non-small cell lung cancer brain metastases;Frontiers in Oncology;2023-11-07
4. Local control strategies for management of NSCLC with oligoprogressive disease;Cancer Treatment Reviews;2023-11
5. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients;Cancer Cell;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3